301201 Chengda Pharmaceuticals
- 21.72
- +0.02+0.09%
Chengda Pharmaceuticals News
Chengda Pharmaceuticals: Announcement regarding the approval of the active pharmaceutical ingredient Dapagliflozin by the CDE.
Chengda Pharmaceutical: Announcement on the Appointment of Deputy General Manager
Chengda Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions for the first half year of 2024
Chengda Pharmaceuticals: Announcement on the Extension of the Implementation Deadline of Some Raised Funds Investment Projects.
Chengda Pharmaceuticals: Legal Opinion of Beijing Zhonglun Wende (Hangzhou) Law Firm on the 2023 Annual General Meeting of Shareholders of Chengda Pharmaceutical Co., Ltd.
Chengda Pharmaceuticals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Chengda Pharmaceuticals: Prompt Announcement on Convening the 2023 Annual General Meeting of Shareholders
Chengda Pharmaceutical: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Chengda Pharmaceutical: Rules of Work for the Nomination Committee of the Board of Directors
Chengda Pharmaceutical: Accounting Services Selection and Recruitment System
Chengda Pharmaceutical: 2023 Internal Control Evaluation Report
Chengda Pharmaceutical: Announcement on Adjusting the Company's Organizational Structure
Chengda Pharmaceutical: Announcement on the 2024 Remuneration Plan for Directors, Supervisors and Senior Management
Chengda Pharmaceutical: Board Strategy Committee Working Rules
Chengda Pharmaceutical: 2023 Financial Results Report
Chengda Pharmaceutical: Working Rules of the Board of Directors Remuneration and Assessment Committee
Chengda Pharmaceutical: Notice on Convening the 2023 Annual General Meeting of Shareholders
Chengda Pharmaceutical: Working System for Special Meetings of Independent Directors
Chengda Pharmaceutical: Rules of Work for the Audit Committee of the Board
Chengda Pharmaceutical: Legal Opinion of Beijing Zhonglun Wende (Hangzhou) Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Chengda Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
No Data